TPSTM is particularly useful in patient management for various carcinomas; in establishing prognosis, in treatment monitoring and in patient follow-up. Performance characteristics are well defined and well documented in management of breast, gastrointestinal, ovarian and prostate cancer patients.


TPSTM is a quantitative serum monoclonal immunoassay with reactivity against the well-defined M3 epitope structure on cytokeratin 18.

TPSTM ELISA is a solid phase sandwich assay based on immunochemical technique. Standards, controls and samples react simultaneously with solid phase catcher antibodies and the HRP conjugated detector antibody (M3) during incubation in the microstrip wells. After washing, the TMB substrate is added. Subsequently the reaction is stopped and the absorbance is read. The developed colour is directly proportional to the concentration of the analyte.